Mentored Patient-Oriented Research for Preventing ASCVD Events
指导预防 ASCVD 事件的以患者为中心的研究
基本信息
- 批准号:10590992
- 负责人:
- 金额:$ 12.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-01-01 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementAcute-Phase ProteinsAddressAdultAgeAtherosclerosisAwardBiological MarkersBody mass indexBostonBranched-Chain Amino AcidsC-PeptideCardiometabolic DiseaseCardiovascular DiseasesCardiovascular systemCause of DeathCessation of lifeClassificationClinicalCollaborationsCoronary heart diseaseCouplingDataDeath RateDiabetes MellitusDiagnosticDietDual-Energy X-Ray AbsorptiometryEducationEnvironmentEpidemiologyEthnic OriginEventFacultyFutureGoalsGuidelinesHealthHealthcareHospitalsImpairmentIndividualInstitutionInsulinInsulin ResistanceInternationalInterventionInvestigationLife StyleLipidsLipoprotein (a)Long-Term EffectsMeasurementMeasuresMentorsMetabolic syndromeMetabolismMid-Career Clinical Scientist Award (K24)ModificationMolecularMolecular EpidemiologyNuclear Magnetic ResonanceObesityOmega-3 Fatty AcidsOnset of illnessOutcomeOverweightPatientsPhysical activityPlasmaPostdoctoral FellowPreventionPrevention ResearchPreventive measurePreventive therapyPublic HealthPublic Health SchoolsRandom AllocationRecommendationRecurrenceResearchResearch PersonnelResearch Project GrantsResourcesRiskRisk FactorsSamplingSmokingSouth AsianTeaching HospitalsTechnologyTestingTrainingUnited Arab EmiratesVitamin DWomanWorkagedatherosclerosis riskcardiometabolic riskcardiometabolismcardiovascular disorder riskcardiovascular healthcardiovascular risk factorcareercareer developmentcase controlclinical practiceclinical riskcoronary eventcost effectivedisorder riskethnic differenceexperiencefollow-upglycosylationhealth recordhigh riskimprovedinflammatory markerinnovationinterestmedical schoolsmenmetabolomicsmortalitymultidisciplinarynew technologynext generationnovelpatient orientedpatient oriented researchpatient populationprecision medicineprematurepreventprogramsrecruitresearch studyrisk stratificationscreeningsextherapeutic targettranslational applicationswaist circumference
项目摘要
Project Summary/Abstract Dr, Mora is a cardiologist cross-trained in epidemiology who has devoted her career to patient-oriented research (POR) in cardiovascular prevention, focusing on the discovery and translational applications of lipid biomarkers of cardiometabolic disease risk, and developing innovative approaches and therapies for preventing cardiometabolic disease. Her POR research has impacted national and international guidelines for clinical practice, In the first K24 cycle, she has mentored more than fifteen preand postdoctoral trainees in POR projects related to lipids, statins, and cardiovascular risk. This has been highlighted in recent years by the achievements of her mentees in presenting their work nationally and internationally, The K24 renewal award will allow her to extend her successful mentoring program. The overall goals of this K24 award are to 1) grow and expand her POR program by providing the next-generation of cardiovascular investigators with opportunities for precision POR in prevention by incorporating technologic advances in high-throughput metabolomics with clinical and health record data as a strategy to improve cardiovascular outcomes; and 2) strengthen and build upon her mentoring program in global cardiovascular health by expanding her POR program to examine cardiometabolic risk factors contributing to premature cardiovascular events. Cardiovascular disease remains the number one cause of death globally, and > 70% of cases can be attributed to cardiometabolic risk factors. Patients with uncontrolled cardiometabolic risk factors are at high risk of suffering from premature and recurrent cardiovascular events. The candidate's ongoing POR projects, exceptional institutional resources, and cost-effective local and international collaborations provide a nurturing environment for the training and career development of junior investigators in POR cardiovascular research. The new research aims proposed in this award will examine a panel of targeted metabolomics with risk of cardiovascular disease from diverse patient populations to better understand how cardiometabolic risk factors could be targeted for precision preventative diagnostic and therapeutic targets. This research program will provide excellent POR opportunities for junior investigators and trainees to be mentored across the full spectrum of clinical, epidemiological, and molecular studies. Results from this mentored POR program will guide future efforts directed at cardiovascular screening, risk stratification, and potentially more targeted precision medicine interventions to improve cardiovascular health. Towards that end, this K24 award will facilitate the progress of Dr, Mora's mentees into the next generation of patient-oriented independent cardiovascular researchers.
项目摘要/摘要莫拉博士是一位接受过流行病学交叉培训的心脏病专家,她的职业生涯致力于心血管疾病预防中以患者为导向的研究(POR),专注于心脏代谢疾病风险的脂质生物标志物的发现和转化应用,并开发预防心脏代谢疾病的创新方法和疗法。她的POR研究影响了国家和国际临床实践指南,在第一个K24周期,她指导了超过15名与脂质,他汀类药物和心血管风险相关的POR项目的博士前和博士后学员。近年来,她的学员在国内和国际上展示他们的工作所取得的成就突出了这一点,K24更新奖将使她能够扩展她成功的指导计划。该K24奖项的总体目标是:1)通过将高通量代谢组学的技术进步与临床和健康记录数据相结合,为下一代心血管研究人员提供预防精确POR的机会,从而发展和扩大她的POR计划,作为改善心血管结局的策略; 2)通过扩大POR项目来检查导致过早心血管事件的心脏代谢风险因素,从而加强和建立她在全球心血管健康方面的指导计划。心血管疾病仍然是全球头号死亡原因,超过70%的病例可归因于心脏代谢风险因素。具有不受控制的心脏代谢风险因素的患者具有患早发性和复发性心血管事件的高风险。候选人正在进行的POR项目,卓越的机构资源,以及具有成本效益的本地和国际合作,为POR心血管研究的初级研究人员的培训和职业发展提供了良好的环境。该奖项提出的新研究目标将研究一组具有不同患者人群心血管疾病风险的靶向代谢组学,以更好地了解如何将心脏代谢风险因素作为精确预防诊断和治疗目标。该研究计划将为初级研究人员和学员提供极好的POR机会,以便在临床,流行病学和分子研究的全方位进行指导。这项指导性POR计划的结果将指导未来针对心血管筛查、风险分层和可能更有针对性的精准医学干预措施的努力,以改善心血管健康。为此,这个K24奖项将促进莫拉博士的学员成为下一代以患者为导向的独立心血管研究人员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAMIA MORA其他文献
SAMIA MORA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAMIA MORA', 18)}}的其他基金
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention
积极解决炎症以预防心血管疾病
- 批准号:
10341419 - 财政年份:2021
- 资助金额:
$ 12.62万 - 项目类别:
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention
积极解决炎症以预防心血管疾病
- 批准号:
10531905 - 财政年份:2021
- 资助金额:
$ 12.62万 - 项目类别:
Patient Centered Approaches to Preventing ASCVD Events
以患者为中心的预防 ASCVD 事件的方法
- 批准号:
10323260 - 财政年份:2018
- 资助金额:
$ 12.62万 - 项目类别:
Patient Centered Approaches to Preventing ASCVD Events
以患者为中心的预防 ASCVD 事件的方法
- 批准号:
10088461 - 财政年份:2018
- 资助金额:
$ 12.62万 - 项目类别:
Total plasma and IgG glycomes, statin therapy and ASCVD events
总血浆和 IgG 糖组、他汀类药物治疗和 ASCVD 事件
- 批准号:
10464886 - 财政年份:2013
- 资助金额:
$ 12.62万 - 项目类别:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
HDL 异质性和功能、他汀类药物治疗和 CVD 结果
- 批准号:
8918813 - 财政年份:2013
- 资助金额:
$ 12.62万 - 项目类别:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
HDL 异质性和功能、他汀类药物治疗和 CVD 结果
- 批准号:
8590899 - 财政年份:2013
- 资助金额:
$ 12.62万 - 项目类别:
Total plasma and IgG glycomes, statin therapy and ASCVD events
总血浆和 IgG 糖组、他汀类药物治疗和 ASCVD 事件
- 批准号:
10217226 - 财政年份:2013
- 资助金额:
$ 12.62万 - 项目类别:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
HDL 异质性和功能、他汀类药物治疗和 CVD 结果
- 批准号:
8862528 - 财政年份:2013
- 资助金额:
$ 12.62万 - 项目类别:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
HDL 异质性和功能、他汀类药物治疗和 CVD 结果
- 批准号:
8916878 - 财政年份:2013
- 资助金额:
$ 12.62万 - 项目类别:
相似海外基金
Proteomic analysis of acute phase proteins of sea cucumber,Apostichopus japonicus
海参急性期蛋白的蛋白质组学分析
- 批准号:
22580208 - 财政年份:2010
- 资助金额:
$ 12.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Biomarkers of the innate immune response to disease in chickens: acute phase proteins and resistance to disease
鸡对疾病的先天免疫反应的生物标志物:急性期蛋白和对疾病的抵抗力
- 批准号:
BB/H016171/1 - 财政年份:2010
- 资助金额:
$ 12.62万 - 项目类别:
Training Grant
DYNAMISM OF GYCAN CHAIN RESPONSE IN ACUTE PHASE PROTEINS ON SEVERE DISEASE CONDITIONS AND MODIFICATION OF GYCAN CHAIN FUNCTION
急性期蛋白对严重疾病状况的多糖链反应动态以及多糖链功能的修饰
- 批准号:
21580392 - 财政年份:2009
- 资助金额:
$ 12.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
EFFECTS OF TETRACYCLINES ON ACUTE PHASE PROTEINS IN SMOKERS W PERIODONTITIS
四环素类药物对牙周炎吸烟者急性期蛋白的影响
- 批准号:
7375340 - 财政年份:2005
- 资助金额:
$ 12.62万 - 项目类别:
EFFECTS OF TETRACYCLINES ON ACUTE PHASE PROTEINS IN SMOKERS W PERIODONTITIS
四环素类药物对牙周炎吸烟者急性期蛋白的影响
- 批准号:
7203622 - 财政年份:2004
- 资助金额:
$ 12.62万 - 项目类别:
Improved methods for quantitation of acute phase proteins in biological samples.
生物样品中急性期蛋白定量的改进方法。
- 批准号:
LP0347774 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
Linkage Projects
Effects of Tetracyclines on Acute Phase Proteins in Smokers w Periodontitis
四环素对牙周炎吸烟者急性期蛋白的影响
- 批准号:
7044281 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
The roles of pro-inflammatory cytokines on induction of acute phase proteins in inflammatory diseases
促炎细胞因子在炎症疾病中诱导急性期蛋白的作用
- 批准号:
15390314 - 财政年份:2003
- 资助金额:
$ 12.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Ceramide and acute phase proteins elevation during aging
衰老过程中神经酰胺和急性期蛋白升高
- 批准号:
6543418 - 财政年份:2002
- 资助金额:
$ 12.62万 - 项目类别:
Ceramide and acute phase proteins elevation during aging
衰老过程中神经酰胺和急性期蛋白升高
- 批准号:
6607625 - 财政年份:2002
- 资助金额:
$ 12.62万 - 项目类别: